Acadia Healthcare Co Azioni (NASDAQ: ACHC)

Ultime notizie per Acadia Healthcare Co (NASDAQ:ACHC) Azioni

ACADIA HEALTHCARE CO INC

Acadia Healthcare Co

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

Acadia Healthcare Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NYSE">ACHC</a>) short percent of float has risen 27.18% since its last report. The company recently reported that it has 6.52 million shares sold short, which is 7.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Acadia Healthcare Co Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744228828_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Acadia Healthcare Co has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Acadia Healthcare Co's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Acadia Healthcare Co's peer group average for short interest as a percentage of float is 4.84%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

ACHC

Is Acadia Healthcare Co Gaining or Losing Market Support?

Guggenheim analyst Jason Cassorla initiates coverage on Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Buy rating and announces Price Target of $36.

News

Price Target

Initiation

Analyst Ratings

Guggenheim Initiates Coverage On Acadia Healthcare Co with Buy Rating, Announces Price Target of $36

U.S. stocks settled mixed on Monday, with the Dow Jones index gaining more than 400 points during the session as investors assessed President Donald Trump's tariff plans. However, the Nasdaq settled lower on Monday as shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 1.2% and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) lost 1.7%.
The S&amp;P 500 declined 5.8% in March, recording its biggest monthly decline since December 2022. The Nasdaq dipped 8.2%, while the Dow tumbled 4.2% last month.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Leo Mariani
<ul>
<li>Analyst Firm: Roth MKM</li>
<li>Ratings Accuracy: 88%</li>
<li>Latest Rating: Initiated coverage on Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Buy rating and a price target of $30 on March 27. This analyst sees around 18% upside in the stock.</li>
<li>Recent News: On March 17, Sable Offshore posted a 2024 net loss of $617.3 million.</li>
</ul>
Analyst: Jay McCanless
<ul>
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated an Outperform rating on Rithm Capital Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) with a price target of $14 on March 28. This analyst sees around 22% surge in the stock.</li>
<li>Recent News: On Feb. 6, Rithm Capital reported better-than-expected first-quarter EPS and sales.</li>
</ul>
Analyst: Ann Hynes 
<ul>
<li>Analyst Firm: Mizuho</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Neutral rating on Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) and slashed the price target from $48 to $37 on March 25. This analyst sees around 21% upside in the stock.</li>
<li>Recent News: On March 6, Acadia Healthcare announced the pricing of $550 million senior notes due 2033.</li>
</ul>
Analyst: Doug Anmuth
<ul>
<li>Analyst Firm: JP Morgan</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) and increased the price target from $38 to $40 on March 27. This analyst sees around 22% upside in the stock.</li>
<li>Recent News: On March 26, Chewy reported a fourth-quarter adjusted EPS of 28 cents, up 55.6% year-over-year, compared to the consensus of 5 cents.</li>
</ul>
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Initiated coverage on Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with an Overweight rating and a price target of $270 on March 26. This analyst sees around 20% upside in the stock.</li>
<li>Recent News: On Feb. 19, the company reported fourth-quarter sales growth of 27.4% year-on-year to $161.82 million, missing the analyst consensus estimate of $164.54 million..</li>
</ul>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Image via Shutterstock

Pre-Market Outlook

Markets

CHWY

NVDA

RITM

TSLA

WING

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

U.S. stocks settled lower on Friday, with the Dow Jones index falling more than 700 points during the session as investors assessed recent tariff-related news.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Leo Mariani
<ul>
<li>Analyst Firm: Roth MKM</li>
<li>Ratings Accuracy: 88%</li>
<li>Latest Rating: Initiated coverage on Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Buy rating and a price target of $30 on March 27. This analyst sees around 16% upside in the stock.</li>
<li>Recent News: On March 17, Sable Offshore posted a 2024 net loss of $617.3 million.</li>
</ul>
Analyst: Jay McCanless
<ul>
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated a Neutral rating on KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) with a price target of $75 on March 25. This analyst sees around 30% surge in the stock.</li>
<li>Recent News: On March 24, KB Home reported worse-than-expected first-quarter EPS and sales.</li>
</ul>
Analyst: Ann Hynes 
<ul>
<li>Analyst Firm: Mizuho</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Neutral rating on Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) and cut the price target from $48 to $37 on March 25. This analyst sees around 23% upside in the stock.</li>
<li>Recent News: On March 6, Acadia Healthcare announced the pricing of $550 million senior notes due 2033.</li>
</ul>
Analyst: Doug Anmuth
<ul>
<li>Analyst Firm: JP Morgan</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) and raised the price target from $38 to $40 on March 27. This analyst sees around 25% upside in the stock.</li>
<li>Recent News: On March 26, Chewy reported a fourth-quarter adjusted EPS of 28 cents, up 55.6% year-over-year, compared to the consensus of 5 cents.</li>
</ul>
Analyst: Josh Sullivan
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Buy rating on Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a price target of $16 on March 25. This analyst sees around 100% upside in the stock.</li>
<li>Recent News: On March 24, Intuitive Machines reported fourth-quarter revenue of $54.66 million, missing analyst estimates of $55.77 million.</li>
</ul>
Read More:
<ul>
<li><a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock"> Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>
Photo: Shutterstock

LUNR

5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Week

8 analysts have shared their evaluations of Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $53.06, a high estimate of $70.00, and a low estimate of $35.00. This current average has decreased by 9.19% from the previous average price target of $58.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1742911269_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Acadia Healthcare Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.50</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$66.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Acadia Healthcare Co's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Acadia Healthcare Co's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
<h3>Key Indicators: Acadia Healthcare Co's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Acadia Healthcare Co displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 4.23%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.21%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Acadia Healthcare Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.07%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Acadia Healthcare Co's ROA stands out, surpassing industry averages. With an impressive ROA of 0.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.68.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Acadia Healthcare Co

Mizuho analyst Ann Hynes maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Neutral and lowers the price target from $48 to $37.

Mizuho Maintains Neutral on Acadia Healthcare Co, Lowers Price Target to $37

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.5% on Friday.
Shares of Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) fell sharply in today's pre-market trading after the company issued second-quarter <a href="https://www.benzinga.com/news/earnings/25/03/44180280/hewlett-packard-enterprise-shares-plunge-after-q1-results-weak-q2-guidance">guidance below estimates</a>.
Hewlett Packard Enterprise reported quarterly earnings of 49 cents per share, in line with the analyst consensus estimate. Quarterly revenue came in at $7.85 billion which beat the analyst consensus estimate of $7.82 billion and an increase over revenue of $6.75 billion from the same period last year.
Hewlett Packard Enterprise estimates second-quarter revenue to be in the range of $7.2 billion to $7.6 billion, versus the $7.93 billion estimate, and EPS of between 28 cents and 34 cents, versus the 50 cent estimate.
Hewlett Packard Enterprise shares tumbled 19.9% to $14.39 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares fell 34.8% to $7.33 in pre-market trading after dipping 20% on Thursday.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) fell 13.7% to $3.62 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Clarus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) shares tumbled 10.8% to $3.80 in pre-market trading following weak quarterly earnings.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) fell 10% to $37.69 in today's pre-market trading after reporting fourth-quarter results.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) fell 6.3% to $7.42 in pre-market trading after the company reported fourth-quarter financial results and missed its adjusted EPS and revenue estimates.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) declined 6% to $28.12 in pre-market trading. Acadia Healthcare announced the pricing of $550 million senior notes due 2033.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 5.2% to $4.5511 in pre-market trading.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 4.3% to $40.94 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44185876/broadcom-genesco-and-3-stocks-to-watch-heading-into-friday">Broadcom, Genesco And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Movers

BBAI

CLAR

SERV

SIFY

Hewlett Packard Enterprise Issues Weak Forecast, Joins Clarus, Samsara And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) (the "Company" or "Acadia") announced today that it has launched a private offering (the "Offering") of $500 million in aggregate principal amount of senior notes due 2033 (the "Notes"), subject to market conditions and other considerations.
The Company intends to use the proceeds from the Offering to prepay a portion of the outstanding borrowings under its existing senior secured revolving line of credit.

Offerings

Acadia Healthcare Plans $500M Debt Offering to Prepay Existing Credit Borrowings

RBC Capital analyst Ben Hendrix maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Outperform and lowers the price target from $64 to $43.

RBC Capital Maintains Outperform on Acadia Healthcare Co, Lowers Price Target to $43

Keybanc analyst Matthew Gillmor maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Overweight and lowers the price target from $70 to $65.

Keybanc Maintains Overweight on Acadia Healthcare Co, Lowers Price Target to $65

Whales with a lot of money to spend have taken a noticeably bullish stance on Acadia Healthcare Co.
Looking at options history for Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $294,214 and 3, calls, for a total amount of $213,245.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $35.0 for Acadia Healthcare Co over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Acadia Healthcare Co stands at 612.0, with a total volume reaching 6,410.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Acadia Healthcare Co, situated within the strike price corridor from $30.0 to $35.0, throughout the last 30 days.
<h3>Acadia Healthcare Co Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740765673_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.2</td>
<td>$2.0</td>
<td>$3.0</td>
<td>$30.00</td>
<td>$74.7K</td>
<td>10</td>
<td align="right">503</td>
</tr>
<tr>
<td>ACHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.4</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$35.00</td>
<td>$71.3K</td>
<td>1.2K</td>
<td align="right">935</td>
</tr>
<tr>
<td>ACHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.0</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$30.00</td>
<td>$70.9K</td>
<td>10</td>
<td align="right">254</td>
</tr>
<tr>
<td>ACHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.1</td>
<td>$30.00</td>
<td>$67.5K</td>
<td>10</td>
<td align="right">871</td>
</tr>
<tr>
<td>ACHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$35.00</td>
<td>$56.0K</td>
<td>1.2K</td>
<td align="right">506</td>
</tr>
</tbody>
</table>

<h3>About Acadia Healthcare Co</h3>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
In light of the recent options history for Acadia Healthcare Co, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Acadia Healthcare Co</h3>
<ul>
<li>Currently trading with a volume of 3,278,446, the ACHC's price is down by -23.92%, now at $30.63. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>Professional Analyst Ratings for Acadia Healthcare Co</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $39.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $35. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Acadia Healthcare Co, maintaining a target price of $44. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Acadia Healthcare Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Market Whales and Their Recent Bets on ACHC Options

WIIM

Acadia Healthcare shares are trading lower after the company reported worse-than-expected Q4 financial results.

Barclays analyst Andrew Mok downgrades Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Overweight to Equal-Weight and lowers the price target from $43 to $35.

Downgrades

Barclays Downgrades Acadia Healthcare Co to Equal-Weight, Lowers Price Target to $35

Throughout the last three months, 6 analysts have evaluated Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $61.92, with a high estimate of $75.00 and a low estimate of $44.50. Marking an increase of 10.18%, the current average surpasses the previous average price target of $56.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1740747618_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Acadia Healthcare Co is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.50</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$66.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Acadia Healthcare Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Acadia Healthcare Co's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>Get to Know Acadia Healthcare Co Better</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>A Deep Dive into Acadia Healthcare Co's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Acadia Healthcare Co's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 8.7%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's net margin is impressive, surpassing industry averages. With a net margin of 8.35%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.28%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Acadia Healthcare Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.18% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.66.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Acadia Healthcare Co Stock

B of A Securities analyst Kevin Fischbeck maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Buy and lowers the price target from $50 to $44.5.

B of A Securities Maintains Buy on Acadia Healthcare Co, Lowers Price Target to $44.5

cadia Healthcare shares are trading lower after the company reported worse-than-expected Q4 financial results.

Earnings

Guidance

Arcadia Healthcare Sees FY25 Adj. EPS $2.50-$2.80; Revenue $3.3B-$3.4B.

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) reported quarterly earnings of $0.64 per share which missed the analyst consensus estimate of $0.71 by 9.86 percent. This is a 26.44 percent decrease over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $774.238 million which missed the analyst consensus estimate of $778.988 million by 0.61 percent. This is a 4.23 percent increase over sales of $742.800 million the same period last year.

Earnings Misses

Acadia Healthcare Co Q4 2024 Adj. EPS $0.64 Misses $0.71 Estimate, Sales $774.238M Miss $778.988M Estimate

AAON

ABCL

ACEL

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Press Releases

ACADIA HEALTHCARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Healthcare Company, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Acadia Healthcare to Participate in March Investor Conferences

ACADIA HEALTHCARE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Acadia Healthcare Company, Inc. - ACHC

Acadia Healthcare Reports Fourth Quarter 2024 Results

Legal

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and Encourages Long-Term Acadia Investors to Contact the Firm

Shareholder Alert: Johnson Fistel, LLP Investigates Domino's Pizza, Masimo, Acadia Healthcare, and American Express—Long-Term Investors are Encouraged to Contact the Firm

Acadia Healthcare Announces Launch of $500 Million Senior Notes Offering

Acadia Healthcare Announces Pricing of $550 Million Senior Notes Due 2033

ACADIA HEALTHCARE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Acadia Healthcare Company, Inc. - ACHC

Comments

Acadia Healthcare Co

Notizie

Ultime notizie per Acadia Healthcare Co (NASDAQ:ACHC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO